Pregnancy in patients with lung cancer is uncommon. There are limited safety data during pregnancy for ALK inhibitors — targeted therapies for patients with non-small cell lung cancer (NSCLC) with ALK gene rearrangements.
Wade Iams, MD, MSCI, Travis Osterman, DO, MS, and colleagues report the case of a patient with metastatic ALK-rearranged NSCLC who was treated with the ALK inhibitor alectinib throughout two pregnancies.